Clinical Trials Browser

Phase 1/2 × tivozanib × Clear all

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03136627 2021-12-06

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Phase 1/2 Completed

28 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01835223 2020-10-28

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

33 enrolled 15 charts

Gastrointestinal

Advanced Adult Hepatocellular Carcinoma

NCT01058655 2017-04-13

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Phase 1/2 Completed

56 enrolled 15 charts

Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT01728181 2013-07-25

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Disease

Clinical Trials

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation